UO Medicina Nucleare, IRCCS IRST
Welcome,         Profile    Billing    Logout  
 10 Trials 
17 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Matteucci, Federica
LYMFOR, NCT06125028: [68Ga]Ga-PentixaFor-PET Imaging for Staging of Marginal Zone Lymphoma

Recruiting
3
148
Europe
[68Ga]Ga-PentixaFor, [68Ga]Ga-PTF, [18F]Fluorodeoxyglucose, [18F]FDG
Pentixapharm AG, Pivotal S.L.
Marginal Zone Lymphoma
06/25
06/25
F-PSMA, NCT04775602 / 2019-002000-41: Experimental Study to Evaluate the Impact of 18 Fluoro-PSMA (18) PET / CT in the Management of Patients with Prostate Cancer.

Completed
2
550
Europe
18F-PSMA
Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori, IRST IRCCS
18F-PSMA, Prostate Cancer
04/23
07/24
LUFOR, NCT06045260 / 2023-000086-14: "Receptor Radionuclide Therapy With 177Lu-DOTATOC

Recruiting
2
100
Europe
177Lu-DOTATOC
Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
Neuroendocrine Tumors, Paraganglioma, Pheochromocytoma
02/25
01/27
LUST, NCT05893381: Lu-PSMA and Stereotactic Radiotherapy Versus Radiotherapy Alone for Prostate Cancer

Recruiting
2
70
Europe
[177Lu]Lu-PSMA I&T, 177Lu-PSMA, Stereotactic Radiotherapy, Ablative stereotactic radiation
Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
Prostate Cancer
09/27
04/32
LUBASKET, NCT05867615: Radiometabolic Therapy With 177Lu PSMA in PSMA PET/CT Positive Advanced/Metastatic Tumours:

Recruiting
2
83
Europe
[177Lu]Lu-PSMA I&T
Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
Cancer
08/26
12/28
FAPrimo, NCT05784597: A Study to Evaluate the Safety and Dosimetry of 68Ga-labelled OncoFAP Derivatives in Solid Tumors

Completed
1
18
Europe
[68Ga]Ga-OncoFAP administration
Philogen S.p.A.
Breast Cancer, Colorectal Cancer, Oesophageal Cancer, Pancreas Adenocarcinoma
10/24
10/24
ARTHE, NCT06390241: Avidination for RadionuclideTHerapy in Nonpalpable Breast Cancer

Terminated
1
18
Europe
Avidin-biotin-Dota-90Y
Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
Breast Cancer
01/25
01/25
GaPSMA, NCT02920229 / 2015-003397-33: 68Ga-PSMA HBED-PET/CT in the Evaluation of the Biochemical Relapse in Patients With a History of Prostate Cancer Radically Treated

Completed
N/A
1230
Europe
68Ga- PSMA
Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori, IRST IRCCS
68Ga-PSMA HBED-PET/CT, Prostate Cancer
10/20
10/20
BASKET GA-PSMA, NCT03453528 / 2016-004376-21: Investigation of PSMA PET/CT as an Imaging Biomarker in Solid Tumors

Completed
N/A
1225
Europe
68Ga-PSMA
Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
Prostate-specific Membrane Antigen, mCRPC or Advanced/Metastatic Solid Tumors
12/24
01/25
BIOPSTAGE, NCT03465579 / 2017-002651-28: Mp-3TMRI and 68Ga-PSMA PET/CT Guided Prostate Biopsy and Tumor Node Metastasis (TNM) Staging.

Terminated
N/A
261
Europe
pelvic MRI, 68Ga-PSMA PET/CT
Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori, IRST IRCCS
68Ga-PSMA PET/CT Guided Prostate Biopsy, Mp-3TMRI Guided Prostate Biopsy, Prostate Cancer, TNM Staging, Diagnosis
09/24
09/24
Sansovini, Maddalena
LUTHREE, NCT03454763 / 2015-004727-31: Optimizing the Interval Between Cycles of PRRT with 177lu-dotatate in Sstr2 Positive Tumors

Active, not recruiting
2
618
Europe
PRRT every 5 weeks, PRRT every 8-10 weeks
Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
Neuroendocrine Tumors
01/25
01/25
LUNET, NCT02489604 / 2013-003165-34: Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE in Advanced Gastro-entero Pancreatic Neuroendocrine Tumors

Terminated
2
70
Europe
177Lu-DOTATATE 25.9 GBq activity, 177Lu-DOTATATE, 177Lu-DOTATATE 18.5 GBq activity
Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
Neuroendocrine Tumors
01/24
01/24
LUFOR, NCT06045260 / 2023-000086-14: "Receptor Radionuclide Therapy With 177Lu-DOTATOC

Recruiting
2
100
Europe
177Lu-DOTATOC
Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
Neuroendocrine Tumors, Paraganglioma, Pheochromocytoma
02/25
01/27
LUBASKET, NCT05867615: Radiometabolic Therapy With 177Lu PSMA in PSMA PET/CT Positive Advanced/Metastatic Tumours:

Recruiting
2
83
Europe
[177Lu]Lu-PSMA I&T
Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
Cancer
08/26
12/28
Romeo, Antonino
LUST, NCT05893381: Lu-PSMA and Stereotactic Radiotherapy Versus Radiotherapy Alone for Prostate Cancer

Recruiting
2
70
Europe
[177Lu]Lu-PSMA I&T, 177Lu-PSMA, Stereotactic Radiotherapy, Ablative stereotactic radiation
Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
Prostate Cancer
09/27
04/32
OVERPASS, NCT05861336 / 2022-001939-88: GEM+Nab-Paclitaxel Plus Losartan Followed by Stereotactic Radiotherapy for Locally Advanced Pancreatic Cancer

Withdrawn
2
34
Europe
Losartan, Gemcitabine, Nab paclitaxel, Stereotactic Body Radiation Therapy
Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
Pancreatic Cancer
12/24
12/24
THRIP, NCT03553212: Twice High Dose External Beam Radiotherapy by Image-guided Tomotherapy for Organ-confined Prostate Cancer Treatment Emulating High Dose Radiation (HDR) Brachytherapy

Terminated
N/A
2
Europe
tomotherapy
Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
Prostate Adenocarcinoma, Radiotherapy; Complications, Tomotherapy
05/23
05/23

Download Options